Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 9/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589675 | 0.96 | SIRT6 (0.57) | SIRT6MAPTALDH1A1HTR6LMNA | |
| SCHEMBL1334925 | 0.91 | SIRT6 (0.76) | SIRT6MAPTALDH1A1HTR6LMNA | |
| SCHEMBL27807044 | 0.88 | SIRT6 (0.60) | SIRT6MAPTALDH1A1HTR6LMNA | |
| SCHEMBL3512166 | 0.88 | MAPT (0.53) | SIRT6MAPTALDH1A1LMNAMAPK1 | |
| SCHEMBL31591510 | 0.87 | SIRT6 (0.49) | SIRT6MAPTALDH1A1HTR6LMNA | |
| SCHEMBL1375198 | 0.87 | MAPT (0.60) | MAPTALDH1A1LMNAMAPK1L3MBTL1 | |
| SCHEMBL1894765 | 0.87 | MAPT (0.52) | SIRT6MAPTALDH1A1HTR6LMNA | |
| SCHEMBL28900077 | 0.86 | SIRT6 (0.81) | SIRT6MAPTALDH1A1HTR6MAPK1 | |
| SCHEMBL1888701 | 0.86 | ALDH1A1 (0.51) | SIRT6MAPTALDH1A1LMNAMAPK1 | |
| SCHEMBL28818852 | 0.85 | SIRT6 (0.54) | SIRT6MAPTALDH1A1HTR6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024379-B | Preparation method and application of 2-amino-4- (4-methyl-1-piperazine) benzoic acid tert-butyl ester | 济南国鼎医药科技有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-117024379-A | Preparation method and application of 2-amino-4- (4-methyl-1-piperazine) benzoic acid tert-butyl ester | 济南国鼎医药科技有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-112939897-A | Preparation method and application of broad-spectrum anti-cancer drug enrotinib intermediate | 上海珈睿医药科技有限公司 | 2021-06-11 | — | — | CN | claimed |
| EP-4603488-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2025-08-20 | — | — | EP | disclosed |
| CN-115916771-B | Multi-target antitumor compound and preparation method and application thereof | 浙江华海药业股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| WO-2024080780-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 고려대학교 산학협력단 | 2024-04-18 | — | — | WO | disclosed |
| CN-117024379-B | Preparation method and application of 2-amino-4- (4-methyl-1-piperazine) benzoic acid tert-butyl ester | 济南国鼎医药科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117024379-B | Preparation method and application of 2-amino-4- (4-methyl-1-piperazine) benzoic acid tert-butyl ester | 济南国鼎医药科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117024379-A | Preparation method and application of 2-amino-4- (4-methyl-1-piperazine) benzoic acid tert-butyl ester | 济南国鼎医药科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-117024379-A | Preparation method and application of 2-amino-4- (4-methyl-1-piperazine) benzoic acid tert-butyl ester | 济南国鼎医药科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116410159-B | Preparation method and application of En Qu Ti-Ni intermediate | 济南国鼎医药科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20090023745-A1 | Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-22 | — | — | US | disclosed |
| EP-1999131-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-10 | — | — | EP | disclosed |
| EP-1968976-A1 | SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-09-17 | — | — | EP | disclosed |
| EP-1963326-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008074749-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007099171-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007099171-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007068619-A1 | SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007068637-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023745-A1 | Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K19 | SIRT6 1409/4885MAPT 2600/4885ALDH1A1 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.